<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ERGOCALCIFEROL</span><br/>(er-goe-kal-si'fe-role)<br/><span class="topboxtradename">Activated Ergosterol, </span><span class="topboxtradename">Calciferol, </span><span class="topboxtradename">Deltalin, </span><span class="topboxtradename">Drisdol, </span><span class="topboxtradename">D-ViSol, </span><span class="topboxtradename">Ostoforte <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Radiostol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Radiostol Forte <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Vitamin D<sub>2</sub>
<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">vitamin d analog</span><br/><b>Prototype: </b>Calcitriol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>8000 IU/mL oral liquid; 50,000 units capsules, tablets; 500,000 IU/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>The name vitamin D encompasses two related fat-soluble substances (sterols) that occur in nature or are synthetically prepared.
         Vitamin D acts like a hormone in that it is distributed through the circulation and plays a major regulatory role.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Maintains normal blood calcium and phosphate ion levels by enhancing their intestinal absorption and by promoting mobilization
         of calcium from bone and renal tubular resorption of phosphate.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Familial hypophosphatemia (vitamin Dresistant rickets), osteomalacia (adult rickets), anticonvulsant-induced rickets
         and osteomalacia, osteoporosis, renal osteodystrophy, hypocalcemia associated with hypoparathyroidism; prophylaxis and treatment
         of nutritional rickets. Also hypophosphatemia in Fanconi's syndrome.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>With varying clinical results in lupus vulgaris, psoriasis, and rheumatoid arthritis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to vitamin D, hypervitaminosis D, hypercalcemia, hyperphosphatemia, renal osteodystrophy with hyperphosphatemia,
         malabsorption syndrome, decreased kidney function. Safe use of amounts in excess of 400 IU (10 mcg) daily during pregnancy
         (category C) is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Coronary disease; lactation; arteriosclerosis (especially in older adults); history of kidney stones.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Nutritional Rickets, Osteomalacia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IM</span> 25125 mcg/d for 612 wk, may need up to 7.5 mg/d in patients with malabsorption<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IM</span> 50125 mcg/d, may need up to 250625 mcg/d in patients with malabsorption<br/><br/><span class="indicationtitle">Vitamin DDependent Rickets</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IM</span> 250 mcg1.5 mg/d, may need up to 12.5 mg/d (prolonged therapy with &gt;2.5 mg/d increases risk of toxicity)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IM</span> 75125 mcg/d, may need up to 1.5 mg/d<br/><br/><span class="indicationtitle">Hypoparathyroidism, Pseudohypoparathyroidism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IM</span> 625 mcg5 mg/d, may need up to 10 mg/d (prolonged therapy with &gt;2.5 mg/d increases risk of toxicity)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IM</span> 1.255 mg/d, (prolonged therapy with &gt;2.5 mg/d increases risk of toxicity)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: 40 U = 1 mcg. Reduce dosage, once symptoms of vitamin D deficiency are relieved, to prevent hypercalcemia.
            			
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give injection deeply, preferably into gluteus maximus and inject slowly. Aspirate carefully. Rotate injection sites.</li>
<li>Preserve in tightly covered, light-resistant containers. Drug decomposes when exposed to light and air.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Fatigue, weakness, vertigo, tinnitus, ataxia, muscle and joint pain, hypotonia (infants), exanthema, rhinorrhea; pruritus;
      mild acidosis. <span class="typehead">Nervous System:</span> Headache, drowsiness, convulsions. <span class="typehead">Digestive:</span> Metallic taste, dry mouth, anorexia, nausea, vomiting, diarrhea, constipation, abdominal cramps. <span class="typehead"> Hematologic:</span> Anemia. <span class="typehead">Musculoskeletal:</span> Calcification of soft tissues (kidneys, blood vessels, myocardium, lungs, skin). <span class="typehead">Urogenital:</span> Nephrotoxicity (polyuria, hyposthenuria, polydipsia, nocturia, casts, albuminuria, hematuria), kidney failure. <span class="typehead">Cardiovascular:</span> Hypertension, cardiac arrhythmias. <span class="typehead">Special Senses:</span> Conjunctivitis (calcific); photophobia. <span class="typehead">Metabolic:</span> Osteoporosis (adults); weight loss, chronic hypervitaminosis D in children (<span class="speceff-life">mental and physical retardation</span>, suppression of linear growth). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Vitamin D may cause false increase in <span class="alt">serum cholesterol</span> measurements <span class="alt">(Zlatkis-Zak reaction).</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cholestyramine,</b>
<b>colestipol,</b>
<b>mineral oil</b> may decrease absorption of vitamin D. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak activity:</span> After 4 wk. <span class="typehead">Duration:</span> 2 mo or more. <span class="typehead"> Distribution:</span> Most of drug first appears in lymph, then concentrates in liver; stored chiefly in liver and to a lesser extent in skin, brain,
      spleen, and bones. <span class="typehead">Metabolism:</span> Metabolized in liver and kidney to active metabolites. <span class="typehead">Elimination:</span> About 50% of oral dose excreted in bile; may be stored in tissues for months. <span class="typehead">Half-Life:</span> 1224 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely patients receiving therapeutic doses of vitamin D must remain under close medical supervision.</li>
<li>Lab tests: When high therapeutic doses are used, progress is followed by frequent determinations (q2wk or more often) of serum
            calcium, phosphorus, magnesium, alkaline phosphatase, BUN, and determinations of urine calcium, casts, albumin, and RBC. Blood
            calcium concentration is generally kept between 9 and 10 mg/dL.
         </li>
<li>Monitor for hypercalcemia; in patients with osteomalacia a decrease in serum alkaline phosphatase may signal the onset of
            hypercalcemia.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid magnesium-containing antacids and laxatives with chronic kidney failure when receiving vitamin D preparations since
            vitamin D increases the risk of magnesium intoxication than other patients.
         </li>
<li>Do not use OTC medications unless approved by physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>